by Peter Ciszewski | May 22, 2020
Ronald Hoffman, MD, Director of the Myeloproliferative Diseases Program at The Icahn School of Medicine at Mount Sinai, describes the findings of an ongoing Phase II clinical trial assessing the safety and efficacy PTG-300 to treat individuals with polycythemia...
by Peter Ciszewski | May 21, 2020
Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology at MD Anderson Center provides a preview of his oral presentation planned for 2020 ASCO Virtual Scientific Program in June that summarized the data from a phase II clinical trial...
by Peter Ciszewski | May 20, 2020
Heather A. Lau, MD, Assistant Professor, Department of Neurology; Associate Director, Division of Neurogenetics; Director, Lysosomal Storage Disease Program at NYU Langone Health provides an overview of the mucopolysaccharidoses (MPSs) a group of rare,...
by Peter Ciszewski | May 20, 2020
Dr. Gary Grohmann, Director of the Australian Immunisation Coalition talks about the possible role AVM0703 may play in treating some of the systems associated with COVID-19. AVM0703 is a repurposed small molecule that is under investigation for treating...
by Peter Ciszewski | May 19, 2020
The U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor, Qinlock (ripretinib) tablets, as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. GIST is a rare...
